Gadicke Ansbert's Form 4 filing
Werewolf Therapeutics, Inc. (HOWL) · filed Dec 4, 2025
- Accession no.
- 0001231919-25-000574
- Filed
- Dec 4, 2025, 6:18 PM ET
- Trade date
- Dec 2-4, 2025
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 3 non-derivative transactions. Open-market sales total $183.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Gadicke AnsbertCIK 0001134655 | Other: Former 10% Owner |
| MPM Asset Management LLCCIK 0001263048 | Other: Former 10% Owner |
| MPM BioImpact LLCCIK 0001687078 | Other: Former 10% Owner |
| UBS Oncology Impact Fund L.P.CIK 0001691428 | Other: Former 10% Owner |
| MPM Oncology Innovations Fund LPCIK 0001719960 | Other: Former 10% Owner |
| Oncology Impact Fund (Cayman) Management L.P.CIK 0001721036 | Other: Former 10% Owner |
| MPM Oncology Innovations Fund GP LLCCIK 0001857903 | Other: Former 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Dec 2, 2025 | Common Stock | SSaleDisposed | −59,277 | $0.89F3 | −$52,756.53 | 4,924,566 | Indirect | |
| Dec 3, 2025 | Common Stock | SSaleDisposed | −57,225 | $0.87F7 | −$49,785.75 | 4,867,341 | Indirect | |
| Dec 4, 2025 | Common Stock | SSaleDisposed | −83,230 | $0.97F10 | −$80,733.1 | 4,784,111 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F3
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.852 to $0.9246 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F7
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.82 to $0.9256 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F10
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.92 to $1.0208 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
This filing is 1 of 2 identical filings due to limitations on number of Reporting Persons. See Form 4 filed by MPM BioVentures 2014, L.P.